Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

The Washington University

Neither a doctor nor a teaching hospital

Research payments

$34,330,028

836 payments

Through program year 2025, The Washington University is reported as receiving $34,330,028 in research payments, across 836 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $2,894,071 272
2024 Research $1,405,463 86
2023 Research $646,701 75
2022 Research $852,968 124
2021 Research $4,162,972 168
2020 Research $8,989,666 95
2019 Research $15,378,187 16

Breakdown

Who paid Research payments · program years 2019–2025
  1. F. Hoffmann-La Roche AG $24,629,967 14 payments
  2. Janssen Research & Development, LLC $2,198,421 34 payments
  3. Pfizer Inc. $1,611,517 85 payments
  4. Genentech, Inc. $977,117 37 payments
  5. ACADIA Pharmaceuticals Inc $914,241 93 payments
  6. Deciphera Pharmaceuticals Inc. $604,514 47 payments
  7. Merck Sharp & Dohme Corporation $473,256 9 payments
  8. United Therapeutics Corporation $325,140 67 payments
  9. Sobi, Inc $240,520 3 payments
  10. Sanofi US Services Inc. $239,704 27 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase Iiiii Randomized Double-Blind Placebo-Controlled Multi Center Study of 2 Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease $22,682,686 9 payments
  2. A Phase Iiiii Randomized, Double-Blind, Placebo-Controlled Multi Center Study of 2 Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease $1,908,531 1 payment
  3. Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With Cdkn2aaltered Hpvunrelated Head and Neck Squamouscell Carcinoma Who Experienced Disease Progression on A Pd1l1 Inhibitor A Multicenter Openlabel Randomized Phase 3 Trial $1,021,758 15 payments
  4. A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer $650,800 7 payments
  5. Ph1 Dose Finding of Cd20 Cd3 TDB in B Cell NHL $594,203 8 payments
  6. Washington University Single Kidney Cell RNA Sequencing $553,734 2 payments
  7. A Master Protocol for the Multi-Cohort, Phase 1/2 Study of Dcc-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies $499,935 19 payments
  8. Acp-2566-004 $277,803 33 payments
  9. Acp-2566-003 $256,855 20 payments
  10. A Randomized Phase II Trial of Salvage Radiotherapy With Standard VS Enhanced Androgen Deprivation Therapy With Enzalutamide in Patients With Postprostatectomy Psa Recurrences With Aggressive Disease Features $219,450 18 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $37,157 4 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record